19
PARTICIPATING COUNTRIESa
Here you can find information on the design of NOVELTY and its sub-studies.
NOVELTY is a global, prospective, observational study, which is following ~12,000 patients over 3 years.
NOVELTY study animation
Watch our short animation to learn more about the NOVELTY study, who is eligible to take part and what we hope to achieve
NOVELTY study infographic
Download a PDF of the NOVELTY study infographic
Who are the patients?
- They have a diagnosis, or suspected diagnosis, of asthma and/or COPD, and include those recently diagnosed
- They are ≥12 years of age (≥18 years of age in many countries)
- They have been enrolled from primary care and specialist care settings.a
Where are the patient data coming from?
- Electronic case report forms (eCRFs) specially designed for this study, completed by the physician every year
- Spirometry measurements taken by the physician
- Patient-reported outcome (PRO) questionnaires completed by the patient every 3 months
- Biosamples from consenting patients.a
What is being investigated?
- Patient characteristics, the burden of illness and treatment patterns over time
- How these are influenced by patient factors, e.g., country of residence, demographics, exposures, symptom history, treatment history, concurrent clinical features, treatment setting, socioeconomic setting and access to healthcare
- Biomarkers and clinical parameters associated with differential outcomes, to identify novel phenotypes* and endotypes†a.
Footnotes
*A phenotype is an observable characteristic or trait of a disease, such as morphology, development, biochemical or physiological properties, without necessarily any implication of a mechanism.
†An endotype is a subtype of a condition, defined by a distinct functional or pathobiological mechanism.